Alport syndrome is an inherited form of kidney disease caused by mutations in the type IV collagen genes (Col4A3, Col4A4 and Col4A5). Type IV collagen is important for maintaining the integrity of the glomerular basement membrane, a vital component in the kidney structure and filtration process. The genetic mutation in the collagen gene results in increased fibrosis, or thickening, in the glomerular basement membrane. https://www.ncbi.nlm.nih.gov/pubmed/23165304
People with Alport syndrome experience a progressive loss of kidney function, which may lead to chronic kidney disease, end stage renal disease requiring dialysis or kidney transplantation, or may even lead to death. Alport syndrome can also cause hearing loss and eye abnormalities during late childhood or early adolescence.
Regulus is currently recruiting participants for the following FDA reviewed clinical trials:
The HERA study
Designed to evaluate the safety and efficacy of an investigational drug (RG-012) in male participants with a diagnosis of Alport syndrome.
The RG012-06 study
Designed to evaluate the safety and tolerability of RG-012 in male and female participants with a diagnosis of Alport syndrome.